Hearing Impairment Among Drug-Resistant Tuberculosis Patients in Rural Eastern Cape: A Retrospective Analysis of Audiometric Findings
- PMID: 40427923
- PMCID: PMC12110855
- DOI: 10.3390/ijerph22050810
Hearing Impairment Among Drug-Resistant Tuberculosis Patients in Rural Eastern Cape: A Retrospective Analysis of Audiometric Findings
Abstract
Hearing loss (HL) is a major global health concern, with drug-induced ototoxicity contributing significantly, particularly in patients undergoing treatment for drug-resistant tuberculosis (DR-TB). In South Africa, where both TB and HIV are prevalent, the risk of treatment-related auditory damage is especially high. This study aimed to assess the prevalence and predictors of hearing impairment among DR-TB patients in rural Eastern Cape, South Africa. A retrospective analysis was conducted on 438 DR-TB patients treated between 2018 and 2020, using pure tone audiometry (PTA) to assess hearing status post-treatment. Demographic, clinical, and lifestyle data were extracted from patient records and analyzed using logistic regression. The overall prevalence of hearing loss was 37.2%. Risk was significantly associated with an older age, a male gender, DR-TB classification (MDR, pre-XDR, and XDR), unsuccessful treatment outcomes, and substance use. Prevalence of HL increased notably in patients aged 70 and older. Lifestyle factors, particularly combined use of tobacco, alcohol, and drugs, were linked to higher odds of HL. These findings underscore the need for routine audiometric screening and personalized treatment monitoring in DR-TB care, especially for high-risk populations. Early identification of ototoxicity risk factors can inform safer treatment regimens and improve patient outcomes in resource-limited settings.
Keywords: adverse drug reaction; audiometric assessment; drug-resistant tuberculosis; hearing loss; ototoxicity; pure tone audiometry.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures






Similar articles
-
Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.Am J Audiol. 2020 Jun 8;29(2):199-205. doi: 10.1044/2020_AJA-19-00103. Epub 2020 Apr 22. Am J Audiol. 2020. PMID: 32320639 Free PMC article.
-
Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.S Afr J Commun Disord. 2019 Jan 30;66(1):e1-e6. doi: 10.4102/sajcd.v66i1.596. S Afr J Commun Disord. 2019. PMID: 30843411 Free PMC article.
-
Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Study of Patients' Characteristics in Selected Healthcare Facilities.Int J Environ Res Public Health. 2024 Nov 30;21(12):1594. doi: 10.3390/ijerph21121594. Int J Environ Res Public Health. 2024. PMID: 39767435 Free PMC article.
-
Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.Indian J Tuberc. 2019 Apr;66(2):279-287. doi: 10.1016/j.ijtb.2019.04.007. Epub 2019 Apr 11. Indian J Tuberc. 2019. PMID: 31151497
-
Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.Int J Tuberc Lung Dis. 2018 Jun 1;22(6):667-674. doi: 10.5588/ijtld.17.0830. Int J Tuberc Lung Dis. 2018. PMID: 29862952 Free PMC article. Review.
References
-
- Tamblay N., Torrente M.C., Huidobro B., Tapia-Mora D., Anabalon K., Polack S., Bright T. Prevalence, risk factors and causes of hearing loss among adults 50 years and older in Santiago, Chile: Results from a rapid assessment of hearing loss survey. Int. J. Audiol. 2023;62:53–61. doi: 10.1080/14992027.2021.1998675. - DOI - PubMed
-
- Pasdelou M.P., Byelyayeva L., Malmström S., Pucheu S., Peytavy M., Laullier H., Hodges D.B., Jr., Tzafriri A.R., Naert G. Ototoxicity: A high risk to auditory function that needs to be monitored in drug development. Front. Mol. NeuroSci. 2024;17:1379743. doi: 10.3389/fnmol.2024.1379743. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources